Our goal is to nurture partnership with a mid to large-size pharmaceutical firm to move this revolutionary therapy into the clinic. Broadly, we seek to partner with firms that have extensive mAb and biologic experience. We will build mutually beneficial partnerships by working with companies that may either lack lead compounds in this niche (targeted anti-cancer therapies that impact tumor stress responses) or have candidates that may act synergistically with CRR9 inhibition. For example, inhibition of the PI3K/Akt/mTOR signaling axis can overcome resistance to many therapies, such as the EGFR inhibitors. Inhibition of Bcl-xL can overcome resistance to the Bcl-2 inhibitors.  Each of these survival factors (PI3K/Akt/mTOR signaling; Bcl-xL) are independently inhibited by our anti-CRR9 antibodies.

Shared Value Proposition: A successful partnership will allow us to leverage scientific expertise from Essential Biotechnology and our partners while decreasing development risks to both. This will be accomplished through funding and product development in collaboration with partners that are well-versed in the translational and clinical aspects of product development. This requires a partnership with a committed industry player(s) that approach product optimization as a collaborative endeavor. Our product pipeline has the potential to vastly increase the value of drugs and biologics that already exist in in the pipelines of our prospective partners.

For more information on partnering with us, email us at